Zacks reiterates recommendation on anti-aging drugmaker Telomir despite 47% YTD loss

In an update, Zacks Small-Cap Research (Zacks SCR) has reiterated its recommendation for investors to take a look at the micro-cap Telomir Pharmaceuticals. The company is focused on reversing biological aging and degenerative diseases, which means "almost unlimited market potential," Zacks SCR explains. 

Investors should consider Telomir Pharmaceuticals, a biotech with a market capitalization of $65 million, before planned human trials of its primary therapy early next year, according to Zacks SCR. It has a $15.50 per share 

target price for Telomir, seven times current quotes. On Friday, July 25, the stock closed at $2.19 per share. Year to date, it is off 47%.

Telomir Pharmaceuticals is developing therapies aimed at addressing the root biological mechanisms behind aging and age-related diseases, including Alzheimer’s and Parkinson’s.

The company’s lead candidate, Telomir-1, is designed to protect telomeres, the protective caps at the ends of chromosomes that progressively shorten with age. Telomere degradation, along with metal reactivity, is believed to increase susceptibility to age-related diseases, according to the company.

Preclinical studies on animals "confirm Telomir-1 can reverse biologic aging, extending life while preserving health," Telomir CEO Erez Aminov said. Last week, Telomir reported that the drug restored mitochondrial function, a critical process for cellular energy production. Mitochondrial dysfunction has been strongly linked to neurodegenerative diseases such as Parkinson’s. The results were “an encouraging signal for therapeutic programs targeting neurodegenerative diseases where mitochondrial dysfunction drives progression,” said Dr. Raphael Mayer, CEO of Smart Assays, a contract research organization specializing in preclinical drug development.

The findings could also have implications for other conditions including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Werner syndrome, and progeria (a rare genetic disorder that causes accelerated aging). To date, the U.S. FDA has approved only one therapy for progeria, which extends life expectancy by an average of 4.3 years but does not halt disease progression, Zacks SCR noted.

Zacks SCR suggests Telomir-1 has the potential not only to slow the aging process, but also to reverse damage caused by a variety of aging-related conditions, "which would be life-changing for millions of patients." That, they conclude, points to "almost unlimited market potential."

The AI translation of this story was reviewed by a human editor.